RSS-Feed abonnieren

DOI: 10.5935/2526-8732.20200021
Challenges in the journey of breast cancer patients in Brazil
Desafios na jornada de pacientes com câncer de mama no Brasil
Autoren
Financial support: Funding to support for the expert meeting and for the preparation of this manuscript was provided by Roche. The authors take full responsibility for the content and conclusions stated in this manuscript. Roche did not influence the content of this publication.
ABSTRACT
The mortality rate of breast cancer (BC) in Brazil is increasing. Procedures that can improve the diagnosis and treatment of BC should be discussed by specialists to improve patient survival. Experts from five different specialties involved in the diagnosis and treatment of BC discussed possible problems and solutions in this context. The discussion focused on diagnosis and treatment of early and metastatic BC. The experts approached different phases of a patient's journey and defined (1) which specialty should be involved, (2) when this specialty should act, (3) what the benefits of a multidisciplinary team might be, (4) what consequences might arise when there is no multidisciplinary team available, and (5) what possible strategies should be implemented to put the recommendations into practice in a setting of scarce resources. This text brings important insights regarding solutions that a multidisciplinary team can provide in the context of BC.
RESUMO
A taxa de mortalidade por câncer de mama (BC) no Brasil está aumentando. Os procedimentos que podem melhorar o diagnóstico e o tratamento do BC devem ser discutidos por especialistas para melhorar a sobrevida do paciente. Especialistas de cinco diferentes especialidades envolvidas no diagnóstico e tratamento do BC discutiram possíveis problemas e soluções nesse contexto. A discussão focou no diagnóstico e tratamento do BC precoce e metastático. Os especialistas abordaram diferentes fases da jornada de um paciente e definiram (1) qual especialidade deveria estar envolvida, (2) quando essa especialidade deveria atuar, (3) quais seriam os benefícios de uma equipe multidisciplinar, (4) quais consequências de não haver equipe multidisciplinar disponível e (5) quais estratégias possíveis devem ser implementadas para colocar as recomendações em prática em um cenário de recursos escassos. Este texto traz informações importantes sobre soluções que uma equipe multidisciplinar pode fornecer no contexto da BC.
Palavras-chave:
Neoplasias da mama - diagnóstico - comunicação interdisciplinar - resultado do tratamentoFinancial support: none to declare.
Publikationsverlauf
Eingereicht: 26. Juni 2020
Angenommen: 17. Juli 2020
Artikel online veröffentlicht:
10. September 2020
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Antônio Carlos Buzaid, Maria Isabel Achatz, Gilberto Luiz da Silva Amorim, Carlos H. Barrios, Filomena Marino Carvalho, Francisco Pimentel Cavalcante, Karina Gondim Moutinho da Conceição, Helenice Gobbi, Clovis Klock, Eduardo Camargo Millen, Vilmar Marques de Oliveira, Arthur Accioly Rosa, Sérgio Daniel Simon. Challenges in the journey of breast cancer patients in Brazil. Brazilian Journal of Oncology 2020; 16: e-20200021.
DOI: 10.5935/2526-8732.20200021
-
REFERENCES
- DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A. et al Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69 (06) 438-451
- INCA. 2019 18.05.2020 Estimativa 2020: Incidência de Câncer no Brasil. < https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf >. Accessed 2020 18.05.2020
- WHO. 2020 18.05.2020 Cancer today: Estimated number of deaths in 2018, worldwide, females, all ages. < https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1 > Accessed 2020 18.05.2020
- Frazier EL, Jiles RB, Mayberry R. Use of screening mammography and clinical breast examinations among black, Hispanic, and white women. Prev Med 1996; 25 (02) 118-125
- de Oliveira EX, Pinheiro RS, Melo EC, Carvalho MS. [Socioeconomic and geographic constraints to access mammography in Brasil, 2003-2008]. Cien Saude Colet 2011; 16 (09) 3649-3664
- Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM. et al Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA 2018; 319 (02) 154-164
- Ministério da Saúde do Brasil. 2018 18.05.2020 Portaria Conjunta nº 19 de 3 de julho de 2018: Diretrizes Diagnósticas e Terapêuticas do Carcinoma de Mama. < http://saude.gov.br/images/pdf/2018/julho/16/Portaria-Conjunta-n-19--PCDT-Carcinomade-Mama.pdf > Accessed 2020 18.05.2020
- INCA. 2019 18.05.2020 A situação do câncer de mama no Brasil: Síntese de dados dos sistemas de informação. < https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/a_situacao_ca_mama_brasil_2019.pdf > Accessed 2020 18.05.2020
- Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG. et al Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast 2019; 44: 113-119
- Tribunal de Contas da União. 2019 18.05.2020 Relatório de auditoria operacional na Política Nacional para a Prevenção e Controle do Câncer. < https://pesquisa.apps.tcu.gov.br/#/documento/acordao-completo/*/NUMACORDAO%253A1944%2520ANOACORDAO%253A2019/DTRELEVANCIA%20desc,%20NUMACORDAOINT%20desc/0/%20?uuid=a3e03690-c806-11e9-94492734c8b180ab > Accessed 2020. 18.05.2020
- Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P. et al Breast cancer. Nat Rev Dis Primers 2019; 5 (01) 66
- Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F. et al 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann Oncol 2018; 29 (08) 1634-1657
- Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 2013; 18 (09) 986-993
- Luftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R. et al Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019; 14 (05) 315-324
- Brasil T. A. SCM, Cardozo I. R., Vargens O. M. C.. A situação do câncer de mama no Brasil: Uma análise do impacto sobre os gastos públicos Seminário Nacional de Pesquisa em emfermagem. 2013
- Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH. et al Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18 (04) 452-478
- Fitzgibbons PL. , Bartley AN, L. CJ. 2020 12.05.2020 Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. Version: Breast Biomarkers 1.4.0.0. < https://documents.cap.org/protocols/cp-breast-biomarker-20-1400.pdf > Accessed 2020. 12.05.2020
- Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL. et al Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38 (12) 1346-1366
- Khoury T. Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules. Am J Clin Pathol 2018; 149 (04) 275-292
- Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS. et al Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018; 142 (11) 1364-1382
- Al-Amri AM. Clinical presentation and causes of the delayed diagnosis of breast cancer in patients with pregnancy associated breast cancer. J Family Community Med 2015; 22 (02) 96-100
- Trufelli DC, Miranda Vda C, Santos MB, Fraile NM, Pecoroni PG, Gonzaga Sde F. et al [Analysis of delays in diagnosis and treatment of breast cancer patients at a public hospital]. Rev Assoc Med Bras 2008; 54 (01) 72-76
- Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ. et al Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. JAMA 2017; 317 (05) 531-534
- Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT. et al Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2019; 30 (08) 1194-1220
- CNEN. 2019 03.05.2020 Profissionais de nível superior habilitados para o preparo, uso e manuseio de fontes radioativas. < https://www.acessoainformação.gov.br > Accessed 2020. 03.05.2020
- Boyages J. Radiation therapy and early breast cancer: current controversies. Med J Aust 2017; 207 (05) 216-222
- Weltman E, Marta GN. Radiotherapy and the SUS: A collapse foretold. Rev Assoc Med Bras 2017; 63 (02) 93-94
- Scheffer M, Cassenote A, Guilloux AGA, Biancarelli A, Miotto BA, Mainardi GM.. 2018 19.05. 2020 Demografia médica no Brasil 2018. < http://www.flip3d.com.br/web/pub/cfm/index10/?numero=15&edicao=4278#page/1 > Accessed 2020. 19.05.2020
- CNEN. 2020 10.05.2020 Profissionais Credenciados; Comissão Nacional de Energia Nuclear/Ministério da Ciência, Tecnologia, Inovações e Comunicações. < http://www.cnen.gov.br/profissionaiscredenciados >. Accessed 2020. 10.05.2020
- Ministério da Saúde do Brasil. 2019 19.05.2020 Censo Radioterapia. < https://www.saude.gov.br/images/pdf/2019/julho/26/paper-radioterapiaALT3.pdf > Accessed 2020. 19.05.2020
- Brum I, Guerra M, Cintra J, BustamanteTeixeira MT. 2017 22.05.2020 Câncer de mama metastático: aspectos clinicopatoló- gicos e sobrevida segundo o sítio de metástase. < http://www.revistas.usp.br/rmrp/article/view/139811 >. Accessed 2020. 22.05.2020
- Kontani K, Hashimoto S, Murazawa C, Norimura S, Tanaka H, Ohtani M. et al Factors responsible for long-term survival in metastatic breast cancer. World J Surg Oncol 2014; 12: 344
-
Garcia-Aranda M,
Redondo M..
Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers (Basel). 2019;11(12)
- Sambi M, Qorri B, Harless W, Szewczuk MR. Therapeutic Options for Metastatic Breast Cancer. Adv Exp Med Biol 2019; 1152: 131-172
- Agência Nacional de Saúde Suplementar. 2018 22.04.2020 Cobertura: Medicamentos antineoplásicos orais. < http://www.ans.gov.br/images/stories/parecer_tecnico/uploads/parecer_tecnico/_PARECER_27-2018_MEDICAMENTOS%20ANTINEOPLSICOS%20ORAIS_VERSO%20FINAL_27122017.pdf >. Accessed 2020 22.04.2020
- Trufelli DC, Miranda Vda C, Santos MB, Fraile NM, Pecoroni PG, Gonzaga Sde F. et al [Analysis of delays in diagnosis and treatment of breast cancer patients at a public hospital]. Rev Assoc Med Bras (1992) 2008; 54 (01) 72-76
- Souza CB, Fustinoni SM, Amorim MH, Zandonade E, Matos JC, Schirmer J. Breast cancer: diagnosisto- treatment waiting times for elderly women at a reference hospital of Sao Paulo, Brazil. Cien Saude Colet 2015; 20 (12) 3805-3816
- Gandamihardja TAK, Soukup T, McInerney S, Green JSA, Sevdalis N. Analysing Breast Cancer Multidisciplinary Patient Management: A Prospective Observational Evaluation of Team Clinical Decision-Making. World J Surg 2019; 43 (02) 559-566
- Conselho Federal de Medicina. 2002 25.03.2020 Resolução CFM nº 1.643/2002. < http://www.portalmedico.org.br/resolucoes/CFM/2002/1643_2002.pdf > Accessed 2020 25.03.2020
- Houssami N, Sainsbury R. Breast cancer: multidisciplinary care and clinical outcomes. Eur J Cancer 2006; 42 (15) 2480-2491